About Peptide Pipeline
An evidence-first peptide drug-development intelligence publication and database.
Peptide Pipeline is a structured intelligence layer for peptide therapeutics. We connect molecules, aliases, sponsors, mechanisms, trials, readouts, regulatory events, deals, and source documents in one versioned system.
Our mission is to make the peptide-therapeutics landscape legible by showing the underlying record before the narrative. Drug-development stories are frequently distorted by alias confusion, phase inflation, sponsor language, changed endpoints, and missing denominators. We surface the evidence that supports each assertion and label what remains unknown.
What we cover
- Assets from discovery through approval, discontinuation, and acquisition
- Company peptide portfolios, platform claims, and deal history
- Clinical trials with registry status, design, and results availability
- Catalysts with precision labels and confidence levels
- Readouts separated by source type: peer-reviewed, registry, conference, company-reported
- Indication, target, and modality landscapes
What we do not do
- No investment advice or price targets
- No medical advice, treatment selection, or patient-level trial matching
- No promotion or sourcing of unapproved substances
- No describing a preclinical candidate as “in trials”